ES News email The latest headlines in your inbox twice a day Monday - Friday plus breaking news updates Enter your email address Continue Please enter an email address Email address is invalid Fill out this field Email address is invalid You already have an account. Please log in Register with your social account or click here to log in I would like to receive lunchtime headlines Monday - Friday plus breaking news alerts, by email Update newsletter preferences

Experts have hailed a "new era" for cancer treatments after achieving "spectacular" results from trials on a new class of drugs.

More than half of patients with advanced melanoma saw tumours shrink or brought under control after undergoing "immunotherapy" in one British-led trial, researchers said.

The treatment, which harnesses the body's immune system to attack cancerous cells, could replace chemotherapy as the standard treatment for cancer within the next five years, it was suggested.

Doctors presented data from a number of trials at the American Society of Clinical Oncology's annual conference in Chicago.

Professor Roy Herbst, chief of medical oncology at Yale Cancer Centre in the US, described some of the findings as "spectacular" and said: "I think we are seeing a paradigm shift in the way oncology is being treated.

"The potential for long-term survival, effective cure, is definitely there."

Professor Peter Johnson, director of medical oncology at Cancer Research UK, said: "The evidence suggests we are at the beginning of a whole new era for cancer treatments."

An international trial on 945 patients with advanced melanoma saw them treated with the drugs ipilimumab and nivolumab.

The treatments stopped cancer advancing for nearly a year in 58 per cent of cases, with tumours stable or shrinking for an average of 11.5 months, researchers found.

This was compared to 19 per cent of cases for ipilimumab alone, with tumours stable or shrinking for an average of 2.5 months, according to the research published in the New England Journal of Medicine.

Dr James Larkin, a consultant at the Royal Marsden Hospital and one of the UK's lead investigators, told the BBC: "By giving these drugs together you are effectively taking two brakes off the immune system rather than one so the immune system is able to recognise tumours it wasn't previously recognising and react to that and destroy them.

"For immunotherapies, we've never seen tumour shrinkage rates over 50% so that's very significant to see.

"This is a treatment modality that I think is going to have a big future for the treatment of cancer."

Dr Alan Worsley, Cancer Research UK's senior science information officer, said: "This research suggests that we could give a powerful one-two punch against advanced melanoma by combining immunotherapy treatments.

"Together these drugs could release the brakes on the immune system while blocking cancer's ability to hide from it.

"But combining these treatments also increases the likelihood of potentially quite severe side effects. Identifying which patients are most likely to benefit will be key to bringing our best weapons to bear against the disease."

Additional reporting by the Press Association.